[Identification of a molecular mechanism for actions of existing medicines and its application for drug development].
As a new strategy for drug discovery and development, we propose here the establishment of drug re-profiling strategy. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have been confirmed already, are examined comprehensively at the molecular level and the results are used for the development of new medicines. For example, identification of the mechanisms underlying the side effects of medicines enables us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines in treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development by pharmaceutical companies.
Department of Analytical Chemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan. mizushima-th@pha.keio.ac.jp
Tohru
T
Mizushima
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D020650:Combinatorial Chemistry Techniques; D004224:Diterpenes; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry; D064420:Drug-Related Side Effects and Adverse Reactions; D057166:High-Throughput Screening Assays; D006801:Humans; D058990:Molecular Targeted Therapy; D004364:Pharmaceutical Preparations; D010599:Pharmacokinetics; D010600:Pharmacology; D013678:Technology, Pharmaceutical
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004224:Diterpenes; D004364:Pharmaceutical Preparations; C031049:geranylgeranylacetone